Device Trial Radar · NCT07518004
ROME GS System Study
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 12, 2026
Primary completion
Aug 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Senseonics, Inc.Public (SENS)
- Sponsor type
- Industry
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.
Conditions
- Diabetes
- Diabetes Melletus, Type 1
- Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring SystemDevice
Eversense 365 Continuous Glucose Monitoring System and ROME GS System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean absolute relative difference (MARD) for paired sensor and reference measurements post-insertion.Time frame: 365 days post-insertion
- Number of device-related or sensor insertion/removal procedure-related serious adverse eventsTime frame: 365 days post-insertion and follow-up
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Headlands Research - AMCR Institute
Escondido, California · Recruiting
Flourish Research - Diablo Clinical Research
Walnut Creek, California · Not yet recruiting
Flourish Research - San Antonio
San Antonio, Texas · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.